Perfectovir is a realizable goal: an HCV revolution

Posted on April 5, 2015

The development of “Perfectovir” is a realizable goal: a revolution in the treatment of Hepatitis C has begun! The key attributes of an optimal HCV treatment regimen were recently outlined by Gregory Dore and Jordan Feld in an invited review article published in the journal Clinical Infectious Diseases (Dore GJ, Feld JJ. Clin Infect Dis. 2015 Mar 11. pii: civ197. [Epub ahead of print]). These key attributes are as follows: Extremely ...

Read More


Two DAA regimen effective in difficult to treat HCV

Regimen of two direct-acting oral antivirals appears effective in patients with difficult to treat HCV subgenotypes 1a and 2b Therapies for HCV genotype 1, 2, and 3 infection have traditionally been peginterferon (pegIFN)-based. PegIFN is associated with adverse events including influenza-like symptoms and depression. Many patients decline PegIFN therapy, and a substantial number of patients with HCV infection have contraindications for ...

Read More


Hepatitis C related complications are increasing!

Posted on April 3, 2015

Hepatitis C-related complications substantially increased between 2005 and 2009: patients with HCV are getting sicker Of all the people in the US living with hepatitis C (HCV), an estimated 76% are adults born during 1945 to 1965: a generation known as the Baby Boomers. A sizeable percentage of Baby Boomers are unaware of their infection status, and given that this population has likely been infected for several decades, it’s not surprising ...

Read More


Can hepatitis C be eradicated in the US?

An important commentary by Brian Edlin and Emily Winkelstein, published in August 2014 in the journal Antiviral Research, outlined key steps that should be taken to accomplish the elimination of hepatitis C in the United States (Edlin BR, Winkelstein ER. Antiviral Res. 2014;110:79-93). This article is freely available on the online AJM Hepatitis C Resource Center (http://hepcresource.amjmed.com). Accomplishing the goal of eradicating hepatitis C ...

Read More


Rapid HCV testing in jails: linkage to care barrier

Posted on April 1, 2015

Rapid HCV testing within jails identifies previously unrecognized cases of HCV infection, but linkage to care after release is a major barrier One-third of all HCV-infected individuals in the USA pass through the criminal justice system each year, so at any given time the correctional population in the USA bears a heavy burden of HCV infection. HCV antibody prevalence among incarcerated adults in North America is estimated to be 29%, and the ...

Read More


HCV RNA Testing in HCV Seropositive Patients

Posted on April 1, 2015

Only 48% of HCV Seropositive Patients Undergo HCV RNA Testing and Only 5% Initiate Therapy The Centers for Disease Control and Prevention recommends one-time hepatitis C virus (HCV) testing of individuals born between 1945 and 1965, with follow-up RNA testing for those with reactive serology. A study published last year in the journal Open Forum Infectious Diseases put perspective on the clinical practice challenges being faced in light of ...

Read More


Barriers to Hepatitis C Screening and Testing

Posted on March 31, 2015

US Healthcare Providers Share Perspectives on Barriers to Hepatitis C Screening and Testing In 2012, the Centers for Disease Control and Prevention (CDC) recommended that all individuals born during 1945 to 1965 (the birth cohort with the highest prevalence of HCV) receive a onetime test for HCV, assessment for alcohol use and intervention as indicated, and linkage to care and treatment as appropriate. CDC’s 2012 recommendations supplement ...

Read More


PCPs report lack of confidence in HCV screening

60% of primary care physicians report a lack of confidence in screening for hepatitis C A survey of Primary Care Physicians (PCPs) actively involved in the care of patients with Hepatitis C (HCV) reveals that up to 60% of PCPs are either not very confident or only somewhat confident about screening individuals for chronic HCV infection. This survey, highlighted by Dr. Edward Lebovics in his article published in the November 2014 issue of The ...

Read More


A Truly Historic Era in Hepatitis C Therapy

Posted on February 23, 2015
Hepatitis C virus

We are entering a truly historic era in hepatitis C therapy. The recent introduction of oral, well-tolerated, limited-duration therapies with over 95% cure rates makes the once unrealistic aspiration of eradicating hepatitis C infection a realizable goal. However, several major hurdles need to be cleared before this objective can be achieved. Foremost is the identification of individuals with hepatitis C infection, and their subsequent linkage ...

Read More


Hepatitis C is a Global Public Health Issue

Posted on February 23, 2015
Hepatitis C virus

Undiagnosed and Untreated Hepatitis C is a Global Public Health Issue Undiagnosed and untreated hepatitis C is a global public health issue, with growing numbers of patients suffering and dying from the consequences of chronic infection, including cirrhosis and hepatocellular carcinoma. HCV infection is typically asymptomatic until significant liver disease occurs, so a primary care provider would have few reasons to order diagnostic tests on ...

Read More